Business Wire

CA-ENCHROMA

14.12.2022 08:01:37 CET | Business Wire | Press release

Share
The Centre Pompidou and EnChroma Improve Arts Experience for Colour Blind Visitors

The Centre Pompidou today announced that colour blind visitors are now able to borrow EnChroma glasses for colour blindness during visits to the iconic museum. The Centre Pompidou is internationally renowned for its collection of modern and contemporary art totaling over 120,000 works – the most extensive in all of Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221213006029/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Robert Delaunay, Manège de cochons, 1922. Don de Mme Sonia Delaunay en 1956. Centre Pompidou, Paris, Musée national d’art moderne - Centre de création industrielle. Colour blind view courtesy of EnChroma. (Graphic: Business Wire)

One in twelve men (8%) and one in 200 women (0.5%) are colour blind – about 2.8 million in France, 30 million in Europe and 350 million globally. With over three million annual visitors, an estimated 128,000 guests to the Centre Pompidou are colour blind. EnChroma glasses will enable colour blind visitors to perceive an expanded range of clear, vibrant colour in artwork at the museum for the first time in their lives.

“Always concerned with offering the best visitor experience to all audiences, the Centre Pompidou is delighted to offer people with colour blindness the possibility of trying EnChroma glasses, a very innovative device in the museum sector,” said David Cascaro, Director of the Public Division, Centre Pompidou.

While people with normal colour vision see over one million shades and hues of colour, colour blind people see only an estimated 10% of them. To the red-green colour blind, colours appear dull and washed out, with some difficult to distinguish from each other. Common colour confusions include green and yellow, grey and pink, purple and blue, and red and brown. This can detract from the ability of colour blind people to fully experience colourful art.

"We are thrilled that one of the world’s foremost visionaries in arts and culture – the Centre Pompidou – is demonstrating its commitment to accessibility and inclusion for those with colour vision deficiencies by loaning EnChroma glasses to guests," said Erik Ritchie, CEO of EnChroma. “Their example will generate more awareness for the prevalence and effects of colour blindness, inspire other museums and organizations to follow their lead, and ultimately expand opportunities for colour blind people to more fully experience colorful, iconic artwork like never before.”

The Centre Pompidou is the first museum in France to support the needs of colour blind guests via the EnChroma Colour Accessibility Program™. The program already helps colour blind people at nearly 200 public institutions – including libraries, schools, universities, national parks, gardens, tourism bureaus and 80+ major museums – more fully experience colours in art, nature and overcome obstacles to learning. Other museums participating in the program include the Gallerie d’Italia in Italy, the Chau Chak Wing Museum in Australia, Centraal Museum Utrecht in The Netherlands, and the Georgia O’Keeffe Museum, Dallas Museum of Art, and Crystal Bridges Museum of American Art in the US.

Special optical filters in EnChroma glasses help colour blind people perceive a wider range of colours and see them more vividly and distinctly. A study by the University of California, Davis, and INSERM, the French National Institute for Health and Medical Research, demonstrated the effectiveness of EnChroma glasses. A separate recent study in the scientific publication Eye-Nature also highlights the benefits of the glasses.

EnChroma Colour Accessibility Program

EnChroma is the leading advocate for accessibility for those with colour blindness. The company donates a pair of glasses for every pair an organization purchases. EnChroma also provides materials for institutions to educate the public or teachers, students and parents about colour blindness and its effects. Public organizations interested in the EnChroma Program can email accessibility@enchroma.com.

About the Centre Pompidou

Since 1977, the Centre Pompidou has been deeply rooted in the city of Paris and open to the world and to innovation. Its iconic building is home to Europe's richest and one of the world's largest collections of modern and contemporary art, in addition to exhibitions, symposiums, festivals, shows, projections, and workshops for young people. Its extremely rich programme at the crossroads of art forms and audiences attracts more than 3.5 million visitors every year. True to its ambition to make culture and creation available to as many people as possible, the Centre Pompidou also develops its regional and international presence. For more information, visit: centrepompidou.fr.

About EnChroma

Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance. Visit enchroma.com to learn more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221213006029/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release

Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of

Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release

The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release

AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye